August 19, 2016 08:55 AM EDTUpdated September 18, 11:36 PM
Bioregnum
Opinion

Thumbs Up. Thumbs Down: On rook­ie mis­takes, a class ac­tion suit and get­ting past fail­ure

 
End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Por­to­la …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

Gly­comine rais­es $115M to see if it can treat rare gly­co­sy­la­tion dis­or­der

At ACIP hear­ing, CDC says it's 'scrap­ing' to re­spond to measles out­break; FDA com­ments on No­vavax halt

GeneDx to buy Fab­ric Ge­nomics for up to $51M

J&J's Du­a­to says 'not tar­iffs, but tax pol­i­cy' is best way to boost US man­u­fac­tur­ing

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times